Search results for "E-F"

showing 10 items of 836 documents

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2006

The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy.We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events.The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best …

MaleOncologymedicine.medical_specialtyFusion Proteins bcr-ablAntineoplastic AgentsKaplan-Meier EstimateChronic phase chronic myelogenous leukemiaDisease-Free SurvivalPiperazineschemistry.chemical_compoundLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOmacetaxine mepesuccinatemedicineHumansneoplasmsbusiness.industryPonatinibCytarabineInterferon-alphaMyeloid leukemiaImatinibGeneral MedicineProtein-Tyrosine KinasesSurvival AnalysisSurvival RateDasatinibPyrimidinesTreatment OutcomeImatinib mesylatechemistryNilotinibBenzamidesImmunologyImatinib MesylateFemalebusinessFollow-Up Studiesmedicine.drugNew England Journal of Medicine
researchProduct

Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Speci…

2005

Abstract Purposes: To elucidate the prognostic value of the immunohistochemical (IHC) expression of Bcl-2, Bax, Cox-2 and Ki-67 antigen in biopsy cores (C) and surgical specimens (SP) of prostate cancer (PC) and to determine the C to SP reproducibility. Material and methods: The IHC study was carried out in 91 patients operated by means of radical prostatectomy (RP) with available formalin-fixed paraffin-embedded material from both C and SP. Results: The IHC expression of Bcl-2 in C and SP was very low (5%). Bax was expressed in almost all the patients and did not show any prognostic value. We observed a good reproducibility between C and SP for all molecules except with Bax. In prostate C,…

MaleOncologymedicine.medical_specialtyPathologyBiopsyUrologymedicine.medical_treatmentDisease-Free SurvivalProstate cancerProstateInternal medicineBiopsyBiomarkers TumormedicineHumansAgedRetrospective Studiesbcl-2-Associated X ProteinProstatectomyUnivariate analysismedicine.diagnostic_testbiologyProstatectomybusiness.industryMembrane ProteinsProstatic NeoplasmsAnatomical pathologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistryKi-67 Antigenmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2Cyclooxygenase 2Ki-67Multivariate AnalysisDisease Progressionbiology.proteinImmunohistochemistrybusinessEuropean Urology
researchProduct

Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Fe…

2017

The aim of this study was to evaluate the acute toxicity profiles of a moderate hypofractionated regimen with volumetric modulated arc therapy (VMAT) in patients with prostate cancer (PC) who underwent radical prostatectomy.From December 2012 to February 2016, 125 patients, previously having undergone radical prostatectomy, received adjuvant (64 patients) or salvage (61 patients) radiotherapy (RT) inside an institutional protocol of moderate hypofractionation schedule using the VMAT technique (Varian RapidArc, Palo Alto, CA). Eligible patients were 85 years old, with an Eastern Cooperative Oncology Group performance status of 0 to 2, histologically proven adenocarcinoma of the prostate with…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyUrinary incontinenceDisease-Free Survival030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancersymbols.namesake0302 clinical medicineInternal medicinemedicineHumansAdjuvantFisher's exact testAgedNeoplasm StagingAged 80 and overProstatectomySalvage TherapyProstate cancerRadiotherapyAdjuvant; Hypofractionation; Prostate cancer; Radiotherapy; Salvage; Oncology; Urologybusiness.industryProstatectomyProstatic NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle AgedProstate-Specific Antigenmedicine.diseaseAcute toxicityRadiation therapyRegimenTreatment OutcomeOncology030220 oncology & carcinogenesissymbolsHypofractionationSalvageRadiation Dose HypofractionationRadiotherapy AdjuvantRadiotherapy Intensity-Modulatedmedicine.symptombusinessRadiotherapy Image-GuidedClinical Genitourinary Cancer
researchProduct

Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentr…

2019

Correspondence.

MaleOncologymedicine.medical_specialtymedicine.medical_treatmentDisease-Free SurvivalRecurrenceRenal DialysisMultiple myelomaDaratumumabInternal medicinemedicineHumansIn patientSingle agentRelapseDialysisMultiple myelomaAgedRetrospective Studiesrelapsebusiness.industryAntibodies MonoclonalDaratumumabRefractory Multiple MyelomaHematologyMiddle Ageddaratumumabmedicine.diseasemultiple myelomaSurvival RatedialysisFemalebusinessDialysisBritish Journal of Haematology
researchProduct

Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia

2017

Abstract Background: The concept of intensive post-remission chemotherapy in acute myeloid leukemia (AML) is based on the observation that despite achievement of a first complete remission (CR) after intensive induction therapy virtually all patients relapse in the absence of further treatment. Moreover, randomized studies showed that intensive post-remission consolidation chemotherapy was superior to prolonged low-dose maintenance therapy in younger patients. With regard to consolidation therapy, the landmark study conducted by the Cancer and Leukemia Group B established the current standard for patients aged 60 years and younger with high-dose cytarabine (HDAC) 3g/m² bidaily on days days …

MaleOncologymedicine.medical_treatmentHematopoietic stem cell transplantationGastroenterologyBiochemistryPolyethylene Glycols0302 clinical medicineMaintenance therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineCytarabineMyeloid leukemiaHematologyMiddle AgedChemotherapy regimen3. Good healthSurvival RateLeukemia Myeloid AcuteLeukemiaOncology030220 oncology & carcinogenesisOriginal ArticleFemalePegfilgrastimmedicine.drugAdultmedicine.medical_specialtyAdolescentFilgrastimImmunologyPlatelet TransfusionFilgrastimDisease-Free Survival03 medical and health sciencesInternal medicineHumansIdarubicinSurvival rateChemotherapybusiness.industryDaunorubicinConsolidation ChemotherapyCell BiologyLength of Staymedicine.diseaseSurgeryConsolidation ChemotherapyTransplantationPlatelet transfusionCytarabinebusiness030215 immunologyBlood
researchProduct

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

2014

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone geneticsandthe recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic rele…

MalePathologyBiochemistryMiceTumor MicroenvironmentMast CellMedicineMast CellsInflammation MediatorAged 80 and overMice KnockoutB-LymphocytesMice Inbred BALB CMesenchymal Stromal CellB-LymphocyteCD40 AntigenCell DifferentiationHematologyMiddle AgedPrognosismedicine.anatomical_structureDisease ProgressionCytokinesFemaleInflammation MediatorsClone (B-cell biology)HumanAdultmedicine.medical_specialtyStromal cellPrognosiCD40 LigandImmunologyDisease-Free SurvivalAnimalsHumansSplenic marginal zone lymphomaCD40 AntigensCytokineB cellAgedCell ProliferationAnimalbusiness.industryMesenchymal stem cellMesenchymal Stem CellsLymphoma B-Cell Marginal ZoneCell BiologyGenes p53medicine.diseaseLymphomaSplenic marginal zone lymphoma bone marrow microenvironment CD40Mast cell sarcomaBone marrowbusinessBlood
researchProduct

Surgical management of pleomorphic adenoma of parotid gland in elderly patients: Role of morphological features

2014

AbstractThe neoplasms of the salivary glands account for 2% of head and neck tumors and the most common form is the Pleomorphic adenoma (PA). Parotid gland is affected from 80% to 90% of cases. In elderly these tumors occur mostly in females. These benign tumors are composed of epithelial and myoepithelial cells that are arranged with various morphological patterns and subtypes. The classification of these tumors is also based on the amount and nature of the stroma. In literature there is an almost complete consensus that, in the major salivary glands, PAs are enclosed by a layer of fibrous tissue often called “capsule” but there is disagreement about the form, extension and thickness of th…

MalePathologymedicine.medical_specialtycapsuleEnucleationAdenoma PleomorphicDisease-Free SurvivalNucleoresection surgical approachPleomorphic adenomaPleomorphic adenomaSatellite NoduleMajor Salivary GlandImage Processing Computer-AssistedHumansMedicineCapsule; Image analysis software; Nucleoresection surgical approach; Parotid gland; Pleomorphic adenomaAgedbusiness.industryImage analysis softwareMedicine (all)Myoepithelial cellCapsulePleomorphic adenoma; Parotid gland; capsuleGeneral MedicineAnatomymedicine.diseaseParotid NeoplasmsParotid glandmedicine.anatomical_structureSuperficial ParotidectomyCapsule; Image analysis software; Nucleoresection surgical approach; Parotid gland; Pleomorphic adenoma; Surgery; Medicine (all)FemaleSurgeryNeoplasm Recurrence LocalbusinessPleomorphic adenoma Parotid gland Capsule Image analysis software Enucleation surgical approachParotid glandInternational Journal of Surgery
researchProduct

Epidemiology of stroke in Europe and trends for the 21st century

2016

International audience; Despite major improvements in primary prevention and acute treatment over the last decades, stroke is still a devastating disease. At the beginning of the 21st century, the age-standardized incidence of stroke in Europe ranged from 95 to 290/100,000 per year, with one-month case-fatality rates ranging from 13 to 35%. Approximately 1.1 million inhabitants of Europe suffered a stroke each year, and ischemic stroke accounted for approximately 80% of cases. Although global stroke incidence is declining, rates observed in young adults are on the rise, thus suggesting a need for strategies to improve prevention. In addition, because of the ageing population, the absolute n…

MalePopulation ageingPediatricsmedicine.medical_specialtyLacunar strokeDijonDisease030204 cardiovascular system & hematologyLacunar stroke03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAcute careEpidemiologymedicineHumans30-day case-fatalityRecurrent strokeTransient ischemic attackStrokeAtrial-fibrillationDepression (differential diagnoses)business.industryIncidenceIncidence (epidemiology)General Medicine[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthEuropeStrokeRisk-factorsCognitive impairmentPopulation registryFemalebusiness030217 neurology & neurosurgeryDemography
researchProduct

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with che…

2013

Abstract Introduction Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-naive patients with metastatic/unresectable non-small cell lung cancer (NSCLC). Methods Patients with histologically or cytologically confirmed NSCLC stage IIIB/IV disease by RECIST (version 1.0) and ECOG-PS 0–1 were enrolled at 15 European sites. Patients received tigatuzumab or placebo intravenously with carboplatin/paclitaxel every 3 weeks (1 cycle) for up to 6 cycles. The primary end point was progression-free survival (PFS). Sec…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPaclitaxelmedicine.medical_treatmentPhases of clinical researchNeutropeniaAntibodies Monoclonal HumanizedPlaceboGastroenterologyDisease-Free SurvivalCarboplatinPlaceboschemistry.chemical_compoundDouble-Blind MethodCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisTigatuzumabLung cancerNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseCarboplatinSurgeryEuropeReceptors TNF-Related Apoptosis-Inducing LigandOncologychemistryPaclitaxelFemalebusinessLung Cancer
researchProduct

Comparative intention-to-treat analysis of the video-assisted thoracoscopic surgery approach to pulmonary segmentectomy for lung carcinoma

2015

Objectives To compare the video-assisted thoracoscopic surgery (VATS) with the open thoracotomy access to pulmonary segmentectomy by the clinical outcomes and long-term survival in lung carcinoma. Methods Non-randomized comparative intention-to-treat study of prospective institutional registry data and survival data of 100 consecutive patients undergoing segmentectomy. Results Within one decade (2002-12), 100 patients with proven or highly suspected lung carcinoma underwent 100 anatomical sub-lobar pulmonary resections (52 typical and 20 atypical segmentectomies, 28 split-lobe procedures). Fifty-six patients were operated by VATS and 44 by thoracotomy access. Comparison of demographic, medi…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtySingle lung ventilationLung Neoplasmsmedicine.medical_treatmentPulmonary segmentectomyDisease-Free SurvivalGermanymedicineCarcinomaHumansPostoperative PeriodProspective StudiesThoracotomyPneumonectomyAgedIntention-to-treat analysisLungThoracic Surgery Video-Assistedbusiness.industryGeneral surgeryCancermedicine.diseaseIntention to Treat AnalysisSurgerySurvival Ratemedicine.anatomical_structureVideo-assisted thoracoscopic surgeryFemaleSurgeryCardiology and Cardiovascular MedicinebusinessInteractive CardioVascular and Thoracic Surgery
researchProduct